Heres what it means for Medicaid enrollees: Medicaid access through the BALANCE Model could begin as early as May 2026 States must opt in voluntarily its not automatic Participating states receive federally negotiated prices from Eli Lilly (Zepbound, Mounjaro) and Novo Nordisk (Wegovy, Ozempic) Wegovy and Zepbound starting doses would cost the program $350/month (reduced from over $1,000) Patients in participating states would pay $50/month for covered GLP-1s Prior authorization and qualifying criteria will still apply This is the biggest potential expansion of GLP-1 access for Medicaid enrollees in history but it depends on your state deciding to participate
Basic labwork including CBC, comprehensive metabolic profile, and HbA1C cash or if insured will bill insurance if the patient has this labwork from other sources within six months of the consultation, no further lab work needs to be done
the neuroprotective mechanisms of NSCs in high-altitude brain injury are still under debate
A large number of bioactive molecules can be cleaved by DPP-4 in vitro , but only a few of these have been demonstrated to be physiological substrates
Stress Reduction and Mental Clarity: Weight loss can be stressful, but at Nuesana, we address both the physical and mental aspects of weight management
Thats why its important to use Wegovy under the guidance of a healthcare provider who can monitor your response and adjust your treatment if needed